Sobi provides and develops specialty and niche pharmaceuticals for rare diseases.
The majority of revenues come from product sales, both proprietary products and products sold under licensing or distribution agreements. The remaining part derives from production of drug substance and royalties.
The product portfolio includes five core products and about 40 partner products, as well as three biological projects in late pivotal clinical development.
Partnering is a core value driver for the company.
An integrated biopharmaceutical company
Operations include capabilities from pre-clinical development, process development and manufacturing of protein pharmaceuticals to market access and commercialization.
The expertise in research and development is mainly focused on late preclinical and clinical development of biologics, as well as on protein manufacturing and process scale-up.
Experienced regulatory affairs
Sobi has the capacity internally to handle the full range of regulatory submissions, such as Orphan Drug Designations, Clinical Trial Applications, requests for Scientific Advice, Pediatric Investigation Plans and Marketing Authorization Applications.
Sobi conducts advanced process development for all stages of the production of recombinant proteins. Resources encompass design, development and implementation of protein production, optimization of production processes, manufacturing of cell banks, bacterial fermentation and cell cultures, cleansing, pre-formulating and scaling-up of the process.
Sobi has two manufacturing facilities, one in Stockholm and one in Umeå.
Strong marketing & sales organization
Sobi has built on the acquisition of Swedish Orphan International in 2010 to create an experienced sales and marketing, medical affairs and market access organization.
The organization covers about 20 countries in Europe and a recently established subsidiary in the US. Sobi is also represented through partners in the Middle East, Israel, Australia and New Zealand.
Sobi has a strong commercial presence in Europe. In 2011 a wholly owned subsidiary was established in the US. During 2012 a wholly owned subsidiary will be set up in the Middle East.